Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Codexis (CDXS)
NASDAQ:CDXS
Holding CDXS?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.04Last Year’s EPS
-$0.1Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Oct 31, 2024
|% Change Since: 68.15%
|Next Earnings Date:Feb 26, 2025
Earnings Call Sentiment|Positive
Codexis demonstrated strong revenue growth and strategic leadership enhancements, with a clear path to profitability by 2026. However, challenges such as a decrease in R&D revenue and increased SG&A expenses were noted. Overall, the sentiment leans towards optimism with focus on future growth and profitability.Company Guidance
During Codexis' Q3 2024 earnings call, management provided guidance for the year, emphasizing several key metrics. They expect to achieve revenue growth through continued expansion in pharma manufacturing and anticipate positive cash flow and profitability by the end of 2026. The company's strong cash position, bolstered by $31 million in net proceeds from institutional investors, is expected to fund operations through 2027. Codexis reported Q3 2024 total revenues of $12.8 million, up from $9.3 million in Q3 2023, with a product gross margin of 61%. The company's financial outlook remains aligned with current analyst estimates for 2024, and they are preparing for strategic investments aimed at enhancing production capabilities and expanding their ECO Synthesis manufacturing platform.Strong Revenue Growth
Total revenues were $12.8 million for Q3 2024, compared to $9.3 million in Q3 2023, driven by an increase in product revenue from $5.4 million to $11.2 million.
Strategic Leadership Hires
Codexis strengthened its executive leadership team with the hires of Georgia Erbez as Chief Financial Officer and Alison Moore as Chief Technical Officer.
Balance Sheet Enhancement
Codexis added $31 million in net proceeds from institutional investors, strengthening the balance sheet.
Path to Profitability
Codexis aims to achieve profitability by the end of 2026 with continued growth in pharma manufacturing and increased orders for RNA ligase offerings.
High Product Gross Margin
Product gross margin increased to 61% in Q3 2024, up from 58% in Q3 2023.
---
CDXS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CDXS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 31, 2024 | $3.14 | $3.50 | +11.46% |
| Aug 08, 2024 | $3.15 | $2.80 | -11.11% |
| May 02, 2024 | $3.34 | $3.92 | +17.37% |
| Feb 28, 2024 | $3.72 | $4.65 | +25.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Codexis (CDXS) report earnings?
Codexis (CDXS) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Codexis (CDXS) earnings time?
Codexis (CDXS) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CDXS EPS forecast?
CDXS EPS forecast for the fiscal quarter 2024 (Q4) is -$0.04.
---